ATE192651T1 - Verwendung von steroidhormonen in zubereitungen zur induzierung von t-zell-lymphokin-erzeugung - Google Patents
Verwendung von steroidhormonen in zubereitungen zur induzierung von t-zell-lymphokin-erzeugungInfo
- Publication number
- ATE192651T1 ATE192651T1 AT90914807T AT90914807T ATE192651T1 AT E192651 T1 ATE192651 T1 AT E192651T1 AT 90914807 T AT90914807 T AT 90914807T AT 90914807 T AT90914807 T AT 90914807T AT E192651 T1 ATE192651 T1 AT E192651T1
- Authority
- AT
- Austria
- Prior art keywords
- production
- cell
- protective
- treatment
- disclosed
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 239000003270 steroid hormone Substances 0.000 title abstract 2
- 230000001939 inductive effect Effects 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 4
- 102000008072 Lymphokines Human genes 0.000 abstract 2
- 108010074338 Lymphokines Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000007423 decrease Effects 0.000 abstract 2
- 230000036737 immune function Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000001681 protective effect Effects 0.000 abstract 2
- 206010062016 Immunosuppression Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000016396 cytokine production Effects 0.000 abstract 1
- 238000000586 desensitisation Methods 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 230000035882 stress Effects 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 239000012646 vaccine adjuvant Substances 0.000 abstract 1
- 229940124931 vaccine adjuvant Drugs 0.000 abstract 1
- 230000005924 vaccine-induced immune response Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41227089A | 1989-09-25 | 1989-09-25 | |
| PCT/US1990/005452 WO1991004030A1 (en) | 1989-09-25 | 1990-09-25 | Use of steroid hormones in compositions for inducing t cell lymphokine production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE192651T1 true ATE192651T1 (de) | 2000-05-15 |
Family
ID=23632331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT90914807T ATE192651T1 (de) | 1989-09-25 | 1990-09-25 | Verwendung von steroidhormonen in zubereitungen zur induzierung von t-zell-lymphokin-erzeugung |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US5540919A (de) |
| EP (1) | EP0494224B1 (de) |
| JP (1) | JP2505313B2 (de) |
| AT (1) | ATE192651T1 (de) |
| AU (2) | AU652130B2 (de) |
| CA (1) | CA2066716A1 (de) |
| DE (1) | DE69033541D1 (de) |
| DK (1) | DK0494224T3 (de) |
| WO (1) | WO1991004030A1 (de) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824313A (en) * | 1989-09-25 | 1998-10-20 | University Of Utah Research Foundation | Vaccine compositions and method for induction of mucosal immune response via systemic vaccination |
| US5837269A (en) * | 1989-09-25 | 1998-11-17 | University Of Utah Research Foundation | Vaccine compositions and method for enhancing an immune response |
| US5919465A (en) * | 1989-09-25 | 1999-07-06 | University Of Utah Research Foundation | Methods for augmenting immunological responses through the administration of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulfate (DHEA-S) |
| US5518725A (en) * | 1989-09-25 | 1996-05-21 | University Of Utah Research Foundation | Vaccine compositions and method for induction of mucosal immune response via systemic vaccination |
| US5562910A (en) * | 1989-09-25 | 1996-10-08 | University Of Utah Research Foundation | Vaccine compositions and method for enhancing an immune response |
| US5292730A (en) * | 1990-08-29 | 1994-03-08 | Humanetics Corporation | Modulation of immune system with Δ5-androstenes |
| US5641766A (en) * | 1990-08-29 | 1997-06-24 | Humanetics Corporation | UP-regulation of immune system with Δ 5-Androstenes |
| US5206008A (en) * | 1991-04-15 | 1993-04-27 | Virginia Commonwealth University | Enhancement of immune response |
| ES2146228T3 (es) * | 1992-02-24 | 2000-08-01 | Univ East Carolina | Metodo para inhibir la carcinogenesis mediante tratamiento con deshidro-epiandrosterona y sus analogos. |
| FR2696934B1 (fr) * | 1992-10-20 | 1995-06-02 | Conservatoire Nal Arts Metiers | Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir. |
| US5407927A (en) * | 1993-04-16 | 1995-04-18 | The Regents Of The University Of California | Treatment of mild depression and restoration of IGF-I levels in aging by dehydroepiandrosterone |
| US20020183288A1 (en) * | 1995-04-03 | 2002-12-05 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| US6242434B1 (en) * | 1997-08-08 | 2001-06-05 | Bone Care International, Inc. | 24-hydroxyvitamin D, analogs and uses thereof |
| US20040043971A1 (en) * | 1995-04-03 | 2004-03-04 | Bone Care International, Inc. | Method of treating and preventing hyperparathyroidism with active vitamin D analogs |
| US5859000A (en) * | 1995-06-07 | 1999-01-12 | University Of Utah Research Foundation | Method for reducing mast cell mediated allergic reactions |
| US5736537A (en) * | 1995-09-12 | 1998-04-07 | Estee Lauder, Inc. | Dehydroep:androsterone sailcylate useful against skin atrophy |
| AU7468196A (en) * | 1995-10-27 | 1997-05-15 | Merck & Co., Inc. | Conjugates of gonadotropin releasing hormone |
| GB9612990D0 (en) * | 1996-06-20 | 1996-08-21 | Stanford Rock Ltd | Compositions and methods for the treatment of chronic infections |
| US5972917A (en) * | 1998-05-29 | 1999-10-26 | Bone Care Int Inc | 1 α-hydroxy-25-ene-vitamin D, analogs and uses thereof |
| ATE246172T1 (de) | 1998-05-29 | 2003-08-15 | Bone Care Int Inc | Verfahren zur herstellung von hydroxy-25-ene vitamin d verbindungen |
| US7229621B2 (en) * | 1998-10-20 | 2007-06-12 | Torrey Pines Institute For Molecular Studies | Method to enhance the immunogenicity of an antigen |
| US20080015174A1 (en) * | 1998-11-24 | 2008-01-17 | Reading Christopher L | Metabolic Disease Treatments |
| US20030083231A1 (en) * | 1998-11-24 | 2003-05-01 | Ahlem Clarence N. | Blood cell deficiency treatment method |
| US6667299B1 (en) * | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
| CA2669753C (en) | 1999-09-30 | 2012-06-26 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment of androgen receptor driven conditions |
| DE19951970A1 (de) * | 1999-10-28 | 2001-05-03 | Bionetworks Gmbh | Arzneimittel für die Toleranzinduktion |
| US6359012B1 (en) | 1999-12-22 | 2002-03-19 | Bone Care International, Inc. | Method for making 24(S)-hydroxyvitamin D2 |
| US6670146B2 (en) | 2000-10-04 | 2003-12-30 | Schering Corporation | Regulatory T cells; methods |
| JP2004537506A (ja) | 2001-03-01 | 2004-12-16 | ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド | 血液細胞欠乏症を治療するためのある種のステロイドの使用 |
| EP1539183A4 (de) | 2002-08-28 | 2007-04-25 | Hollis Eden Pharmaceuticals | Therapeutische behandlungsmethoden |
| US20050101581A1 (en) * | 2002-08-28 | 2005-05-12 | Reading Christopher L. | Therapeutic treatment methods 2 |
| US20050014734A1 (en) * | 2003-07-18 | 2005-01-20 | Genovate Biotechnology Co., Ltd. | Modulation of interleukin-10 by DHEA |
| US7094775B2 (en) | 2004-06-30 | 2006-08-22 | Bone Care International, Llc | Method of treating breast cancer using a combination of vitamin D analogues and other agents |
| WO2008046576A1 (en) * | 2006-10-16 | 2008-04-24 | Transgene S.A. | Use of glucocorticoid antagonists in vaccination |
| WO2010088393A2 (en) * | 2009-01-28 | 2010-08-05 | Antigen Express, Inc. | Li-kay hybrid peptides that modulate the immune response to influenza |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4004003A (en) * | 1974-08-28 | 1977-01-18 | The Upjohn Company | 25-Hydroxycalciferol compounds for treatment of steroid-induced osteoporosis |
| US4080448A (en) * | 1974-11-13 | 1978-03-21 | Mirsky Louis H | Method of treating cellular stress |
| US4110446A (en) * | 1977-07-14 | 1978-08-29 | Wisconsin Alumni Research Foundation | Method of treating milk fever in dairy cattle with 1,25-dihydroxycholecalciferol |
| JPS55139320A (en) * | 1979-04-16 | 1980-10-31 | Teijin Ltd | Bone metabolism regulator |
| FR2494697A1 (fr) * | 1980-11-21 | 1982-05-28 | Roussel Uclaf | Nouveaux derives steroides 3-amines, leurs sels, procede et intermediaires de preparation, application a titre de medicaments et compositions les renfermant |
| US4661447A (en) * | 1981-04-17 | 1987-04-28 | Shanksville Corporation N.V. | Regulatory glycoprotein for immune response and the use there of in the production of T-cell growth factor |
| JPH0751511B2 (ja) * | 1982-03-15 | 1995-06-05 | 味の素株式会社 | インターロイキン２を含有してなる癌治療剤 |
| US4542129A (en) * | 1982-08-16 | 1985-09-17 | Norman Orentreich | DHEA Formulations and methods for treating dry skin |
| US4496556A (en) * | 1982-08-16 | 1985-01-29 | Norman Orentreich | Topical applications for preventing dry skin |
| DE3241113A1 (de) * | 1982-11-06 | 1984-05-10 | Bayer Ag, 5090 Leverkusen | Vakzinen mit zuschlagstoffen |
| US4610978A (en) * | 1983-03-22 | 1986-09-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions containing 1α-hydroxycholecalciferol for topical treatment of skin disorders and methods employing same |
| US4518595A (en) * | 1983-07-19 | 1985-05-21 | The Jackson Laboratory | Method for treating diabetes using DHEA compounds |
| CA1314870C (en) * | 1983-08-02 | 1993-03-23 | Arthur G. Schwartz | Steroids useful as anti-cancer, anti-obesity, anti-hyperglycemic, anti-autoimmune and anti-hypercholesterolemic agents |
| US4617299A (en) * | 1983-12-19 | 1986-10-14 | Knepper Paul A | Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension |
| US4666898A (en) * | 1983-12-28 | 1987-05-19 | Jackson Lab. | Treatment of obesity, diabetes and other symptoms of hypercorticoidism using etiocholanolones |
| US4628052A (en) * | 1985-05-28 | 1986-12-09 | Peat Raymond F | Pharmaceutical compositions containing dehydroepiandrosterone and other anesthetic steroids in the treatment of arthritis and other joint disabilities |
| DK585886A (da) * | 1985-12-24 | 1987-06-25 | Takeda Chemical Industries Ltd | Immunstimulerende middel og anvendelse deraf |
| EP0230574A3 (de) * | 1986-01-31 | 1989-03-22 | Yale University | Pharmazeutische Zusammensetzungen gegen durch LAV/HTLV-III-Virus verursachte Infektionen und ihre Verwendung |
| US4778750A (en) * | 1986-02-19 | 1988-10-18 | Imreg, Inc. | Diagnostic methods for immune function |
| US4820693A (en) * | 1986-05-22 | 1989-04-11 | Angiogenics, Ltd. | Method and composition for arresting angiogenesis and capillary, cell or membrane leakage |
| US5000956A (en) * | 1987-03-09 | 1991-03-19 | Alza Corporation | Prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug |
| EP0282156B1 (de) * | 1987-03-09 | 1991-04-17 | Alza Corporation | Zusammensetzung zur Vorbeugung einer Kontaktallergie durch gleichzeitiges Verabreichen eines Kortikosteroids mit einem sensiblisierenden Arzneistoff |
| NL194728C (nl) * | 1987-04-16 | 2003-01-07 | Hollis Eden Pharmaceuticals | Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan. |
| US5407684A (en) * | 1988-12-30 | 1995-04-18 | Virginia Commonwealth University | Use of DHEA as a medicinal |
| US5098899A (en) * | 1989-03-06 | 1992-03-24 | Trustees Of Boston University | Method for therapeutically treating psoriatic arthritis using vitamin D analogues and metabolites |
-
1990
- 1990-09-25 CA CA 2066716 patent/CA2066716A1/en not_active Abandoned
- 1990-09-25 JP JP51381890A patent/JP2505313B2/ja not_active Expired - Lifetime
- 1990-09-25 AU AU65019/90A patent/AU652130B2/en not_active Ceased
- 1990-09-25 DK DK90914807T patent/DK0494224T3/da active
- 1990-09-25 WO PCT/US1990/005452 patent/WO1991004030A1/en active IP Right Grant
- 1990-09-25 DE DE69033541T patent/DE69033541D1/de not_active Expired - Fee Related
- 1990-09-25 AT AT90914807T patent/ATE192651T1/de not_active IP Right Cessation
- 1990-09-25 EP EP19900914807 patent/EP0494224B1/de not_active Expired - Lifetime
-
1993
- 1993-02-16 US US08/018,471 patent/US5540919A/en not_active Expired - Fee Related
-
1994
- 1994-09-20 US US08/295,068 patent/US5827841A/en not_active Expired - Fee Related
- 1994-10-10 AU AU75727/94A patent/AU667018B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2505313B2 (ja) | 1996-06-05 |
| DK0494224T3 (da) | 2000-08-07 |
| US5827841A (en) | 1998-10-27 |
| CA2066716A1 (en) | 1991-03-26 |
| AU6501990A (en) | 1991-04-18 |
| EP0494224A1 (de) | 1992-07-15 |
| EP0494224A4 (en) | 1992-10-14 |
| AU7572794A (en) | 1994-12-08 |
| EP0494224B1 (de) | 2000-05-10 |
| AU652130B2 (en) | 1994-08-18 |
| DE69033541D1 (de) | 2000-06-15 |
| JPH05502856A (ja) | 1993-05-20 |
| WO1991004030A1 (en) | 1991-04-04 |
| AU667018B2 (en) | 1996-02-29 |
| US5540919A (en) | 1996-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE192651T1 (de) | Verwendung von steroidhormonen in zubereitungen zur induzierung von t-zell-lymphokin-erzeugung | |
| ES2153444T3 (es) | Anticuerpos contra interleucina-4 mamifera, y peptidos utiles como antigenos en su produccion. | |
| ATE142691T1 (de) | Proteine mit faktor-viii-aktivität, verfahren zu deren herstellung unter verwendung von genetisch modifizierten zellen und diese enthaltende pharmazeutische zusammensetzungen | |
| ATE342730T1 (de) | Hla bindepeptide und ihre verwendungen | |
| AR006942A1 (es) | Manufactura de un medicamento para inhibir una respuesta antigeno- especifica, composiciones farmaceuticas y celulas t anergicas antigeno-especificas | |
| DE3382789D1 (de) | Tierische Interferone, Verfahren bei deren Herstellung, dieselben enthaltende Zusammensetzungen, kodierende DNS-Sequenzen hierfür und diese Sequenzen enthaltende Expressionsvektoren und dadurch transformierte Zellen. | |
| Bragg et al. | Protein synthesis in mouse spermatozoa | |
| SE8701934D0 (sv) | Enhanced expression of human interleukin-2 in mammalian cells | |
| ES2074046T5 (es) | Procedimiento de construccion de una linea celular animal para la preparacion de beta-interferon humano. | |
| Barker et al. | Gamma‐interferon induced human keratinocyte HLA‐DR synthesis: the role of dermal activated T lymphocytes | |
| Highet et al. | Corticosteroid regulation of IL-1 production may be responsible for deficient immune suppressor function during the metamorphosis of Xenopus laevis, the South African clawed toad | |
| DE3855634D1 (de) | Innerhalb des alpha-Locus gelegenes T-Zell-Rezeptor-Gen und DNA-Konstruktionen | |
| Hall et al. | Molecular size and subunit structure of the fourth component of guinea pig complement | |
| SE8303925D0 (sv) | Interferon e | |
| Lancaster et al. | Isolation of a purified skin test antigen from Blastomyces dermatitidis yeast-phase cell wall | |
| Klapper Jr et al. | Inhibition of peptic digestion of serum albumin by fatty acids | |
| HUP9800520A2 (hu) | Génexpresszió emlős sejtekben | |
| ROBBOY et al. | Zone electrophoresis and prolactin activity of rat adenohypophysis cultivated in vitro | |
| Mizobe et al. | Induction of a specific protein by oestradiol in rat pineals in culture | |
| Beloff-Chain et al. | The release of insulin from pancreatic islets of lean and obese mice stimulated in vitro by pituitary glands from obese mice and by high glucose concentrations | |
| Lindahl-Kiessling et al. | A factor in amniotic fluid inhibiting phytohemagglutinin (PHA) induced lymphocyte growth | |
| Lee-Own et al. | Cell-free translation of messenger RNAs of embryonic tooth organs: synthesis of the major extracellular matrix proteins | |
| Kyriakidis et al. | The fate of nuclear RNA migrated into isolated mitochondria | |
| SUNDARAM et al. | Immunochemical studies of human growth hormone, ovine prolactin, bovine growth hormone and a tryptic digest of bovine growth hormone | |
| ATE336569T1 (de) | Induzierte zelluläre immunitität durch aktivierung der th1 und unterdrückung der th2 antwort durch macrophhagen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |